Abrocitinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis, Pruritus, Chronic Pruritus, Chronic Prurigo, Skin Diseases

Trial Timeline

Sep 9, 2021 → Jul 11, 2022

NCT ID

NCT05038982

About Abrocitinib

Abrocitinib is a phase 2 stage product being developed by Pfizer for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT05038982. Target conditions include Prurigo Nodularis, Pruritus, Chronic Pruritus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04564755	Pre-clinical	Completed	—	—	Atopic Dermatitis
NCT05466578	Pre-clinical	Active	—	—	Severe Uncontrolled Atopic Dermatitis
NCT06899204	Pre-clinical	Recruiting	Jan 13, 2026	Sep 30, 2026	Atopic Dermatitis
NCT06807281	Phase 3	Recruiting	Dec 2, 2025	Feb 22, 2032	Atopic Dermatitis
NCT06807268	Phase 3	Recruiting	Jul 24, 2025	May 2, 2027	Eczema
NCT05721937	Pre-clinical	Recruiting	Jul 25, 2023	Dec 31, 2027	Atopic Dermatitis
NCT05689151	Pre-clinical	Recruiting	Mar 9, 2023	Dec 31, 2027	Atopic Dermatitis
NCT05391061	Pre-clinical	Recruiting	Jan 7, 2023	Nov 22, 2027	Dermatitis, Atopic
NCT05038982	Phase 2	Completed	Sep 9, 2021	Jul 11, 2022	Prurigo Nodularis

Competing Products

20 competing products in Prurigo Nodularis

See all competitors

Product	Company	Stage	Hype Score
Vixarelimab + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
Upadacitinib	AbbVie	Approved	85
Pimecrolimus + Hydrocortisone + Pimecrolimus	Novartis	Phase 2	52
Rocatinlimab + Placebo	Amgen	Phase 3	76
Dupilumab SAR231893 (REGN668)	Sanofi	Pre-clinical	22
Dupilumab	Sanofi	Phase 3	76
Dupilumab	Sanofi	Pre-clinical	22
Dupilumab	Sanofi	Pre-clinical	22
Ruxolitinib Cream 1.5%	Incyte	Phase 1	30
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	74
INCB054707 + Placebo	Incyte	Phase 2	49
Povorcitinib + Placebo	Incyte	Phase 3	74
Povorcitinib + Placebo	Incyte	Phase 3	74
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	74
CDX-0159 + Normal saline	Celldex Therapeutics	Phase 1	28
barzolvolimab	Celldex Therapeutics	Phase 2	47
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	60
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	60
Nalbuphine ER Tablets + Placebo Tablets	Trevi Therapeutics	Phase 2/3	60
serlopitant + Placebo	Vyne Therapeutics	Phase 2	44

Other Products from Pfizer